etbx-071
Vaccineexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 24, 2018 (NCT03481816)
Timeline
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06765954 | Phase 2 | Jun 1, 2025 | ImmunityBio, Inc. |
| NCT06765902 | Phase 2 | Jan 31, 2025 | ImmunityBio, Inc. |
| NCT03481816 | Phase 1 | Jul 24, 2018 | National Cancer Institute (NCI) |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmunityBio, Inc. | For profit | 2 | 2 | 1 | 2025 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1